Transgene
Develops cancer immunotherapies using vaccines and oncolytic viruses.
TNG | PA
Overview
Corporate Details
- ISIN(s):
- FR0005175080
- LEI:
- 969500PDJW8N0FSGGK69
- Country:
- France
- Address:
- 400 BOULEVARD GONTHIER D'ANDERNACH, 67400 ILLKIRCH-GRAFFENSTADEN
- Website:
- https://www.transgene.fr/en/
Description
Transgene is a clinical-stage biotechnology company that designs and develops immunotherapies for the treatment of cancer. The company's strategy is based on two proprietary technology platforms. The myvac® platform is used to create individualized neoantigen therapeutic vaccines, such as its clinical candidate TG4050, which leverages advanced genetic engineering and artificial intelligence. The invir.IO® platform is dedicated to developing innovative, multifunctional oncolytic viruses engineered to directly destroy cancer cells and modulate the tumor microenvironment, thereby enhancing the patient's immune response against the tumor.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-07-09 17:45 |
Transgene Appoints Seasoned Industry Executive Emmanuelle Quilès to Board of Di…
|
English | 255.1 KB | ||
| 2025-06-19 08:00 |
Transgene Completes Initial Patient Screening in Phase II Part of TG4050 Trial …
|
English | 310.5 KB | ||
| 2025-06-19 08:00 |
Transgene finalise la sélection initiale de patients pour la partie Phase II de…
|
French | 304.7 KB | ||
| 2025-06-13 08:30 |
Transgene participera à plusieurs rencontres avec des acteurs clés de la biotec…
|
French | 304.7 KB | ||
| 2025-06-13 08:30 |
Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders
|
English | 277.0 KB | ||
| 2025-06-03 08:00 |
Transgene organise un webinaire sur les résultats positifs de TG4050 dans les c…
|
French | 269.2 KB | ||
| 2025-06-03 08:00 |
Transgene to Host Webcast on Positive TG4050 Head and Neck Cancer Data Presente…
|
English | 282.5 KB | ||
| 2025-06-01 19:15 |
Transgene et NEC présentent une survie sans récidive durable, accompagnée d’une…
|
French | 378.8 KB | ||
| 2025-06-01 19:15 |
Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Re…
|
English | 394.4 KB | ||
| 2025-05-22 17:45 |
Transgene présente des données de survie sans récidive à 24 mois sur l’ensemble…
|
French | 378.1 KB | ||
| 2025-05-22 17:45 |
Transgene to Present 24-month Disease-Free Survival Data from All Patients in P…
|
English | 412.3 KB | ||
| 2025-05-15 17:45 |
Assemblée Générale Mixte de Transgene du 15 mai 2025
|
French | 315.4 KB | ||
| 2025-05-15 17:45 |
Transgene's Combined General Meeting of May 15, 2025
|
English | 285.9 KB | ||
| 2025-04-24 17:45 |
Transgene Provides Business and Financial Update for Q1 2025
|
English | 310.4 KB | ||
| 2025-04-24 17:45 |
Transgene fait le point sur ses activités et sa situation financière au premier…
|
French | 452.4 KB |
Automate Your Workflow. Get a real-time feed of all Transgene filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Transgene
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Transgene via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-30 | N/A | Other | Other | 30,898,876 | 32,999,999.57 EUR |
| 2023-05-26 | N/A | Other | Buy | 29,325 | N/A |
Peer Companies
